NGeneBio is moving ahead with plans to have the test cleared for diagnostic use in Korea, while envisioning a 2019 submission to the US FDA.
Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
The molecular diagnostic company plans to avoid the IPO process but go public in China through a reverse merger with an auto parts maker.
BioNano plans to develop structural variant assays on its Irys system for diagnostic use in China as a first step in bringing its technology to the clinic.
The assays will incorporate BioNano's Irys next-generation mapping platform, which is designed to image, map, and analyze DNA at the single-molecule level.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.